Phibro Animal Health (NASDAQ:PAHC) issued an update on its FY 2022 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $1.250-$1.320 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.340. The company issued revenue guidance of $840 million-$870 million, compared to the consensus revenue estimate of $850.23 million.
Phibro Animal Health stock traded down $0.44 during mid-day trading on Wednesday, reaching $21.66. The stock had a trading volume of 2,550 shares, compared to its average volume of 134,487. The company has a debt-to-equity ratio of 1.60, a quick ratio of 1.72 and a current ratio of 3.04. Phibro Animal Health has a fifty-two week low of $16.27 and a fifty-two week high of $31.00. The stock’s 50-day simple moving average is $24.38 and its 200-day simple moving average is $25.69. The firm has a market capitalization of $877.32 million, a PE ratio of 16.49 and a beta of 0.51.
Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Tuesday, August 24th. The company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Phibro Animal Health had a return on equity of 23.68% and a net margin of 6.53%. On average, research analysts forecast that Phibro Animal Health will post 1.3 earnings per share for the current fiscal year.
Separately, Barclays lowered Phibro Animal Health from an equal weight rating to an underweight rating and set a $23.00 price target on the stock. in a report on Wednesday, July 7th.
In other news, Director E Thomas Corcoran bought 5,000 shares of the stock in a transaction on Monday, August 30th. The shares were purchased at an average cost of $23.68 per share, for a total transaction of $118,400.00. Following the completion of the purchase, the director now directly owns 20,000 shares in the company, valued at approximately $473,600. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 50.05% of the company’s stock.
A hedge fund recently raised its stake in Phibro Animal Health stock. Morgan Stanley increased its stake in Phibro Animal Health Co. (NASDAQ:PAHC) by 210.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 180,782 shares of the company’s stock after purchasing an additional 122,489 shares during the quarter. Morgan Stanley owned about 0.45% of Phibro Animal Health worth $5,222,000 at the end of the most recent quarter. Institutional investors own 52.74% of the company’s stock.
About Phibro Animal Health
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines.
Featured Story: Understanding Relative Strength Index
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.